Matricellular proteins and matrix metalloproteinases mark the inflammatory and fibrotic response in human cardiac allograft rejection

European Heart Journal

Volumn 34, Issue 25, 2013, Pages 1930-1941

  Vanhoutte, Davy ^a,b   Van Almen, Geert C ^c   Van Aelst, Lucas N L ^a   Van Cleemput, Johan ^a   Droogné, Walter ^a   Jin, Yu ^c   Van De Werf, Frans ^a   Carmeliet, Peter ^d,e   Vanhaecke, Johan ^a   Papageorgiou, Anna Pia ^a,c   Heymans, Stephane ^a,c  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^b CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^c MAASTRICHT UNIVERSITY   (Netherlands)

^d DEPARTMENT OF PLANT SYSTEMS BIOLOGY   (Belgium)

^e UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

Biomarker; Cardiac matrix; Heart transplantation; Inflammation; Matricellular proteins; Metalloproteinases; Rejection

Indexed keywords

BIOLOGICAL MARKER; CONNECTIVE TISSUE GROWTH FACTOR; GELATINASE A; GELATINASE B; INTERLEUKIN 6; MATRIX METALLOPROTEINASE; MATRIX METALLOPROTEINASE 14; OSTEONECTIN; PROTEOGLYCAN; SYNDECAN 1; TESTICAN 1; THROMBOSPONDIN 1; THROMBOSPONDIN 2; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; CYTOKINE; TISSUE INHIBITOR OF METALLOPROTEINASE;

ARTICLE; CARDIAC GRAFT REJECTION; CARDITIS; CD3+ T LYMPHOCYTE; CD69+ T LYMPHOCYTE; CLINICAL ARTICLE; EXTRACELLULAR MATRIX; HEART MUSCLE BIOPSY; HEART MUSCLE FIBROSIS; HEART TRANSPLANTATION; HUMAN; HUMAN TISSUE; INFLAMMATORY INFILTRATE; MONOCYTE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEIVER OPERATING CHARACTERISTIC; T LYMPHOCYTE; ALLOGRAFT; FEMALE; FIBROSIS; GRAFT REJECTION; HEART MUSCLE; MALE; METABOLISM; MIDDLE AGED; MYOCARDITIS; PATHOLOGY;

ALLOGRAFTS; BIOLOGICAL MARKERS; CYTOKINES; EXTRACELLULAR MATRIX; FEMALE; FIBROSIS; GRAFT REJECTION; HEART TRANSPLANTATION; HUMANS; MALE; MATRIX METALLOPROTEINASES; MIDDLE AGED; MONOCYTES; MYOCARDITIS; MYOCARDIUM; PROTEOGLYCANS; T-LYMPHOCYTES; TISSUE INHIBITOR OF METALLOPROTEINASES;

EID: 84880236416     PISSN: 0195668X     EISSN: 15229645     Source Type: Journal    
DOI: 10.1093/eurheartj/ehs375     Document Type: Article

References (33)

1. Stewart S, Winters GL, Fishbein MC, Tazelaar HD, Kobashigawa J, Abrams J, Andersen CB, Angelini A, Berry GJ, Burke MM, Demetris AJ, Hammond E, Itescu S, Marboe CC, McManus B, Reed EF, Reinsmoen NL, Rodriguez ER, Rose AG, Rose M, Suciu-Focia N, Zeevi A, Billingham ME. Revision of the 1990 working formulation for the standardization of nomenclature in the diagnosis of heart rejection. J Heart Lung Transplant 2005;24:1710-1720.
2. Dobaczewski M, Gonzalez-Quesada C, Frangogiannis NG. The extracellular matrix as a modulator of the inflammatory and reparative response following myocardial infarction. J Mol Cell Cardiol 2010;48:504-511.
3. Spinale FG. Myocardial matrix remodeling and the matrix metalloproteinases: influence on cardiac form and function. Physiol Rev 2007;87:1285-1342.
4. Frangogiannis NG. Matricellular proteins in cardiac adaptation and disease. Physiol Rev 2012;92:635-688.
5. Booth AJ, Bishop DK. TGF-beta, IL-6, IL-17 and CTGF direct multiple pathologies of chronic cardiac allograft rejection. Immunotherapy 2010;2:511-520.
6. Vanhoutte D, Schellings MW, Gotte M, Swinnen M, Herias V, Wild MK, Vestweber D, Chorianopoulos E, Cortes V, Rigotti A, Stepp MA, Van de Werf F, Carmeliet P, Pinto YM, Heymans S. Increased expression of syndecan-1 protects against cardiac dilatation and dysfunction after myocardial infarction. Circulation 2007;115:475-482.
7. Teng YH, Aquino RS, Park PW. Molecular functions of syndecan-1 in disease. Matrix Biol 2012;31:3-16.
8. Li J, Brown LF, Laham RJ, Volk R, Simons M. Macrophage-dependent regulation of syndecan gene expression. Circ Res 1997;81:785-796.
9. Vanhoutte D, Heymans S. TIMPs and cardiac remodeling: 'embracing the MMP-independent-side of the family'. J Mol Cell Cardiol 2010;48:445-453.
10. Campbell LG, Ramachandran S, Liu W, Shipley JM, Itohara S, Rogers JG, Moazami N, Senior RM, Jaramillo A. Different roles for matrix metalloproteinase-2 and matrix metalloproteinase-9 in the pathogenesis of cardiac allograft rejection. Am J Transplant 2005;5:517-528.
11. Eaton VL, Lerret NM, Velasquez-Lopera MM, John R, Caicedo M, DeCresce RP, Jaramillo A. Enhanced allograft survival and modulation of T-cell alloreactivity induced by inhibition of MMP/ADAM enzymatic activity. Am J Transplant 2008;8: 507-516.
12. de Groot-Kruseman HA, Mol WM, Niesters HG, Maat AP, van Gelder T, Balk AH, Weimar W, Baan CC. Differential intragraft cytokine messenger RNA profiles during rejection and repair of clinical heart transplants. A longitudinal study. Transpl Int 2003;16:9-14.
13. Holweg CT, Potena L, Luikart H, Yu T, Berry GJ, Cooke JP, Valantine HA, Mocarski ES. Identification and classification of acute cardiac rejection by intra-graft transcriptional profiling. Circulation 2011;123:2236-2243.
14. Fahmy NM, Yamani MH, Starling RC, Ratliff NB, Young JB, McCarthy PM, Feng J, Novick AC, Fairchild RL. Chemokine and chemokine receptor gene expression indicates acute rejection of human cardiac transplants. Transplantation 2003;75: 72-78.
15. Marboe CC, Billingham M, Eisen H, Deng MC, Baron H, Mehra M, Hunt S, Wohlgemuth J, Mahmood I, Prentice J, Berry G. Nodular endocardial infiltrates (Quilty lesions) cause significant variability in diagnosis of ISHLT Grade 2 and 3A rejection in cardiac allograft recipients. J Heart Lung Transplant 2005;24: S219-S226.
16. Shulzhenko N, Morgun A, Zheng XX, Diniz RV, Almeida DR, Ma N, Strom TB, Gerbase-DeLima M. Intragraft activation of genes encoding cytotoxic T lymphocyte effector molecules precedes the histological evidence of rejection in human cardiac transplantation. Transplantation 2001;72:1705-1708.
17. Ramsperger-Gleixner M, Spriewald BM, Tandler R, Kondruweit M, Amann K, Weyand M, Ensminger SM. Increased transcript levels of TNF-alpha, TGF-beta, and granzyme B in endomyocardial biopsies correlate with allograft rejection. Exp Clin Transplant 2011;9:387-392.
18. Zhao XM, Hu Y, Miller GG, Mitchell RN, Libby P. Association of thrombospondin-1 and cardiac allograft vasculopathy in human cardiac allografts. Circulation 2001;103:525-531.
19. Bayliss J, Maguire JA, Bailey M, Leet A, Kaye D, Richardson M, Bergin PJ, Dowling J, Thomson NM, Stein AN. Increased vascular endothelial growth factor mRNA in endomyocardial biopsies from allografts demonstrating severe acute rejection: a longitudinal study. Transpl Immunol 2008;18:264-274.
20. Deng MC, Erren M, Kammerling L, Gunther F, Kerber S, Fahrenkamp A, Assmann G, Breithardt G, Scheld HH. The relation of interleukin-6, tumor necrosis factor-alpha, IL-2, and IL-2 receptor levels to cellular rejection, allograft dysfunction, and clinical events early after cardiac transplantation. Transplantation 1995;60:1118-1124.
21. Ram M, Sherer Y, Shoenfeld Y. Matrix metalloproteinase-9 and autoimmune diseases. J Clin Immunol 2006;26:299-307.
22. Krukemeyer MG, Moeller J, Morawietz L, Rudolph B, Neumann U, Theruvath T, Neuhaus P, Krenn V. Description of B lymphocytes and plasma cells, complement, and chemokines/receptors in acute liver allograft rejection. Transplantation 2004; 78:65-70.
23. Tsai EW, Wallace WD, Gjertson DW, Reed EF, Ettenger RB. Significance of intra-graft CD138+ lymphocytes and p-S6RP in pediatric kidney transplant biopsies. Transplantation 2010;90:875-881.
24. Rodrigo E, Lopez Hoyos M, Escallada R, Ruiz JC, Fresnedo GF, Heras M, Pinera C, Ramos MA, Cotorruelo JG, Arias M. Changes in serum concentrations of matrix metalloproteinases in kidney transplantation. Transplant Proc 2000;32:517-518.
25. Beeh KM, Beier J, Kornmann O, Micke P, Buhl R. Sputum levels of metalloproteinase-9 and tissue inhibitor of metalloproteinase-1, and their ratio correlate with airway obstruction in lung transplant recipients: relation to tumor necrosis factor-alpha and interleukin-10. J Heart Lung Transplant 2001;20: 1144-1151.
26. Ermolli M, Schumacher M, Lods N, Hammoud M, Marti HP. Differential expression of MMP-2/MMP-9 and potential benefit of an MMP inhibitor in experimental acute kidney allograft rejection. Transpl Immunol 2003;11:137-145.
27. Booth AJ, Csencsits-Smith K, Wood SC, Lu G, Lipson KE, Bishop DK. Connective tissue growth factor promotes fibrosis downstream of TGFbeta and IL-6 in chronic cardiac allograft rejection. Am J Transplant 2010;10:220-230.
28. Heymans S, Luttun A, Nuyens D, Theilmeier G, Creemers E, Moons L, Dyspersin GD, Cleutjens JP, Shipley M, Angellilo A, Levi M, Nube O, Baker A, Keshet E, Lupu F, Herbert JM, Smits JF, Shapiro SD, Baes M, Borgers M, Collen D, Daemen MJ, Carmeliet P. Inhibition of plasminogen activators or matrix metalloproteinases prevents cardiac rupture but impairs therapeutic angiogenesis and causes cardiac failure. Nat Med 1999;5:1135-1142.
29. Tsukioka K, Suzuki J, Fujimori M, Wada Y, Yamaura K, Ito K, Morishita R, Kaneda Y, Isobe M, Amano J. Expression of matrix metalloproteinases in cardiac allograft vasculopathy and its attenuation by anti MMP-2 ribozyme gene transfection. Cardiovasc Res 2002;56:472-478.
30. Koenig GC, Rowe RG, Day SM, Sabeh F, Atkinson JJ, Cooke KR, Weiss SJ. MT1-MMP-dependent remodeling of cardiac extracellular matrix structure and function following myocardial infarction. Am J Pathol 2012;180:1863-1878.
31. Heymans S, Schroen B, Vermeersch P, Milting H, Gao F, Kassner A, Gillijns H, Herijgers P, Flameng W, Carmeliet P, Van de Werf F, Pinto YM, Janssens S. Increased cardiac expression of tissue inhibitor of metalloproteinase-1 and tissue inhibitor of metalloproteinase-2 is related to cardiac fibrosis and dysfunction in the chronic pressure-overloaded human heart. Circulation 2005;112:1136-1144.
32. Lopez B, Gonzalez A, Diez J. Circulating biomarkers of collagen metabolism in cardiac diseases. Circulation 2010;121:1645-1654.
33. Sivakumar P, Gupta S, Sarkar S, Sen S. Upregulation of lysyl oxidase and MMPs during cardiac remodeling in human dilated cardiomyopathy. Mol Cell Biochem 2008;307:159-167.